{"id":"https://openalex.org/W2098103756","doi":"https://doi.org/10.2174/157340012798994858","title":"Second-Generation Antipsychotic Agents: A Review of Safety Profiles","display_name":"Second-Generation Antipsychotic Agents: A Review of Safety Profiles","publication_year":2012,"publication_date":"2012-01-14","ids":{"openalex":"https://openalex.org/W2098103756","doi":"https://doi.org/10.2174/157340012798994858","mag":"2098103756"},"language":"en","primary_location":{"id":"doi:10.2174/157340012798994858","doi":"https://doi.org/10.2174/157340012798994858","is_oa":false,"landing_page_url":"https://doi.org/10.2174/157340012798994858","pdf_url":null,"source":{"id":"https://openalex.org/S173574272","display_name":"Current Psychiatry Reviews","issn_l":"1573-4005","issn":["1573-4005","1875-6441"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","poland-40"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Psychiatry Reviews","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2098103756"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5077393862","display_name":"V.I. Yurkov","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vladimir Yurkov","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048248370","display_name":"Sarita Jha","orcid":"https://orcid.org/0009-0003-7486-8857","observed_orcids":["https://orcid.org/0009-0003-7486-8857"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sarita Jha","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103220032","display_name":"David M Collins","orcid":"https://orcid.org/0000-0002-4327-5907","observed_orcids":["https://orcid.org/0000-0002-4327-5907"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David M. Collins","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5072519261","display_name":"Silvia Alessi\u2010Severini","orcid":"https://orcid.org/0000-0002-6543-7719","observed_orcids":["https://orcid.org/0000-0002-6543-7719"]},"institutions":[{"id":"https://openalex.org/I46247651","display_name":"University of Manitoba","ror":"https://ror.org/02gfys938","country_code":"CA","type":"education","lineage":["https://openalex.org/I46247651"]}],"countries":["CA"],"is_corresponding":true,"raw_author_name":"Silvia Alessi-Severini","raw_affiliation_strings":["Faculty of Pharmacy, University of Manitoba, Winnipeg, Manitoba, R3E 0T5, Canada.,Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Faculty of Pharmacy, University of Manitoba, Winnipeg, Manitoba, R3E 0T5, Canada.,Canada","institution_ids":["https://openalex.org/I46247651"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5072519261"],"corresponding_institution_ids":["https://openalex.org/I46247651"],"apc_list":null,"apc_paid":null,"fwci":0.196,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.54499924,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"8","issue":"1","first_page":"49","last_page":"68"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10854","display_name":"Bipolar Disorder and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/atypical-antipsychotics","display_name":"atypical antipsychotics","score":1.0},{"id":"https://openalex.org/keywords/antipsychotic-safety","display_name":"antipsychotic safety","score":0.8199999928474426},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.7390000224113464},{"id":"https://openalex.org/keywords/tolerability","display_name":"tolerability","score":0.8659999966621399},{"id":"https://openalex.org/keywords/weight-gain","display_name":"weight gain","score":0.7630000114440918},{"id":"https://openalex.org/keywords/dyslipidemia","display_name":"dyslipidemia","score":0.9819999933242798},{"id":"https://openalex.org/keywords/glycemic-abnormalities","display_name":"glycemic abnormalities","score":0.8980000019073486},{"id":"https://openalex.org/keywords/hyperprolactinemia","display_name":"hyperprolactinemia","score":1.0},{"id":"https://openalex.org/keywords/tardive-dyskinesia","display_name":"tardive dyskinesia","score":0.9850000143051147},{"id":"https://openalex.org/keywords/movement-disorders","display_name":"movement disorders","score":0.8420000076293945},{"id":"https://openalex.org/keywords/cardiovascular-events","display_name":"cardiovascular events","score":0.9369999766349792},{"id":"https://openalex.org/keywords/clozapine","display_name":"clozapine","score":0.7839999794960022},{"id":"https://openalex.org/keywords/ziprasidone","display_name":"ziprasidone","score":0.9359999895095825},{"id":"https://openalex.org/keywords/aripiprazole","display_name":"aripiprazole","score":0.9419999718666077},{"id":"https://openalex.org/keywords/risperidone","display_name":"risperidone","score":0.8610000014305115},{"id":"https://openalex.org/keywords/olanzapine","display_name":"olanzapine","score":0.9240000247955322},{"id":"https://openalex.org/keywords/quetiapine","display_name":"quetiapine","score":0.7950000166893005},{"id":"https://openalex.org/keywords/first-line-treatment-selection","display_name":"first-line treatment selection","score":0.531000018119812},{"id":"https://openalex.org/keywords/adolescents","display_name":"adolescents","score":0.6880000233650208},{"id":"https://openalex.org/keywords/long-term-pharmacotherapy","display_name":"long-term pharmacotherapy","score":0.843999981880188}],"concepts":[{"id":"https://openalex.org/C2777270317","wikidata":"https://www.wikidata.org/wiki/Q205517","display_name":"Ziprasidone","level":4,"score":0.8963510990142822},{"id":"https://openalex.org/C2780211496","wikidata":"https://www.wikidata.org/wiki/Q411188","display_name":"Aripiprazole","level":3,"score":0.8798960447311401},{"id":"https://openalex.org/C2776619155","wikidata":"https://www.wikidata.org/wiki/Q201872","display_name":"Olanzapine","level":3,"score":0.7528083324432373},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.7432469725608826},{"id":"https://openalex.org/C2780634440","wikidata":"https://www.wikidata.org/wiki/Q408535","display_name":"Quetiapine","level":3,"score":0.7170722484588623},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7024068832397461},{"id":"https://openalex.org/C2780057945","wikidata":"https://www.wikidata.org/wiki/Q412443","display_name":"Risperidone","level":3,"score":0.7008349895477295},{"id":"https://openalex.org/C2780494398","wikidata":"https://www.wikidata.org/wiki/Q208144","display_name":"Antipsychotic","level":3,"score":0.612415611743927},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6007658243179321},{"id":"https://openalex.org/C2780864610","wikidata":"https://www.wikidata.org/wiki/Q221361","display_name":"Clozapine","level":3,"score":0.5472670197486877},{"id":"https://openalex.org/C2778999636","wikidata":"https://www.wikidata.org/wiki/Q418785","display_name":"Amisulpride","level":4,"score":0.5412812232971191},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.536481499671936},{"id":"https://openalex.org/C2776921671","wikidata":"https://www.wikidata.org/wiki/Q758295","display_name":"Atypical antipsychotic","level":4,"score":0.4244348108768463},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3813154399394989},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.3538035750389099},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.18974870443344116}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.2174/157340012798994858","doi":"https://doi.org/10.2174/157340012798994858","is_oa":false,"landing_page_url":"https://doi.org/10.2174/157340012798994858","pdf_url":null,"source":{"id":"https://openalex.org/S173574272","display_name":"Current Psychiatry Reviews","issn_l":"1573-4005","issn":["1573-4005","1875-6441"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","poland-40"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Psychiatry Reviews","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2728473268","https://openalex.org/W2170200230","https://openalex.org/W1972281638","https://openalex.org/W3038177017","https://openalex.org/W2132327224","https://openalex.org/W3139849147","https://openalex.org/W4229883964","https://openalex.org/W3021720083","https://openalex.org/W2025729658","https://openalex.org/W2087618621"],"abstract_inverted_index":{"Early":[0],"clinical":[1],"trials":[2],"had":[3],"suggested":[4],"a":[5,74,181,185],"better":[6],"safety":[7,51],"profile":[8],"for":[9,122,127,184,228],"the":[10,21,43,46,58,148],"second-generation":[11,82],"antipsychotics":[12],"(SGAs;":[13],"e.g.":[14,26],"risperidone,":[15],"olanzapine,":[16],"quetiapine,":[17],"aripiprazole)":[18],"compared":[19],"to":[20,64,179,212,216,233,238],"older":[22],"first-generation":[23],"agents":[24,128],"(FGAs;":[25],"haloperidol":[27],"and":[28,48,79,106,115,138,222,242],"phenothiazines);":[29],"however,":[30],"new":[31],"long-term":[32,68],"studies":[33,69,89],"have":[34,135,165,201],"determined":[35],"that":[36,49,112],"important":[37],"adverse":[38,77,95,197,218],"events":[39,78,96,198],"are":[40,125,144],"associated":[41],"with":[42,73,117,147,171],"use":[44],"of":[45,67,70,81,87,151,192],"SGAs":[47,217],"their":[50],"profiles":[52],"differ":[53],"significantly.":[54],"This":[55],"article":[56],"reviews":[57],"most":[59],"recent":[60],"publications":[61],"(September":[62],"2007":[63],"September":[65],"2011)":[66],"antipsychotic":[71,83],"pharmacotherapy":[72],"focus":[75],"on":[76],"tolerability":[80],"medications.":[84],"A":[85],"total":[86],"55":[88],"were":[90,97],"included.":[91],"Most":[92],"commonly":[93],"reported":[94,203],"weight":[98,139],"gain,":[99],"dyslipidemias,":[100],"glycemic":[101],"abnormalities,":[102],"hyperprolactinemia,":[103],"movement":[104,193],"disorders":[105],"cardiovascular":[107,123],"events.":[108,219],"It":[109],"would":[110],"appear":[111,211],"overweight":[113],"patients":[114,189,206],"those":[116],"dyslipidemia":[118],"or":[119,132,173],"risk":[120,150,191],"factors":[121],"disease":[124],"candidates":[126],"such":[129],"as":[130,159],"aripiprazole":[131],"ziprasidone,":[133],"which":[134],"neutral":[136],"lipid":[137],"gain":[140],"profiles.":[141],"Patients":[142],"who":[143,164],"not":[145,155,168],"comfortable":[146],"potential":[149],"developing":[152],"hyperprolactinemia":[153],"should":[154,167,224],"be":[156,169,213,226],"prescribed":[157],"risperidone":[158],"first":[160],"line":[161],"therapy.":[162],"Those":[163],"arrhythmias":[166],"treated":[170],"clozapine":[172],"ziprasidone.":[174],"More":[175],"challenging":[176],"it":[177],"is":[178],"make":[180],"straight":[182],"recommendation":[183],"first-line":[186],"treatment":[187,243],"in":[188,204,236],"at":[190],"disorders.":[194],"Severe":[195],"SGA-induced":[196],"including":[199],"death":[200],"been":[202],"elderly":[205],"affected":[207],"by":[208],"dementia.":[209],"Adolescents":[210],"more":[214],"susceptible":[215],"Potential":[220],"risks":[221],"benefits":[223],"always":[225],"considered":[227],"each":[229],"individual":[230],"patient":[231],"prior":[232],"therapy":[234],"initiation":[235],"order":[237],"minimize":[239],"discontinuation":[240],"rates":[241],"failure.":[244],"Keywords:":[245],"Adverse":[246],"events,":[247],"Antipsychotics,":[248],"Long-term":[249],"studies,":[250],"Safety,":[251],"Second-generation":[252],"antipsychotics,":[253],"Tolerability,":[254],"Glucose,":[255],"Tardive":[256],"Dyskinesia,":[257],"HEMATOLOGICAL,":[258],"olanzapine":[259]},"counts_by_year":[{"year":2013,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}